☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Biohaven
Biohaven Acquires Rights for BHV-8000 to Treat Immune-Mediated Brain Disorders
March 23, 2023
Biohaven to Acquire Channel Biosciences for ~$3B
February 28, 2022
Biohaven Entered into an Exclusive License and Research Agreement with KU Leuven to Develop and Commercialize BHV-2100 for Chronic...
January 10, 2022
Biohaven Reports Results of Zavegepant in P-III Study for the Treatment of Migraine
December 7, 2021
PharmaShots Weekly Snapshots (November 08, 12, 2021)
November 12, 2021
PharmaShots Weekly Snapshots (May 31 - June 4, 2021)
June 4, 2021
Load more...
Back to Home
Modal title
×
Modal body text goes here.